全部 标题 作者
关键词 摘要


Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate

DOI: 10.4137/CMT.S3778

Full-Text   Cite this paper   Add to My Lib

Abstract:

Peripheral T-cell lymphomas (PTCL) represent about 12%–15% of non-Hodgkin lymphomas and are characterized for being a molecularly heterogenous group of diseases. The optimal treatment for PTCLs remains to be defined as they are usually refractory to existing therapies and carry a poor prognosis. Pralatrexate (PDX), a rationally designed antifolate drug, was granted FDA approval as a single agent for the treatment of relapsed/refractory PTCL in 2009. Because of its favorable toxicity profile and activity, Pralatrexate has become a major compound for patients with refractory PTCL.

Full-Text

comments powered by Disqus